Abstract:Introduction: During the coronavirus disease 2019 (COVID-19) pandemic, a large number of critically ill and severe COVID-19 patients meet the diagnostic criteria for sepsis and even septic shock. The treatments for COVID-19 patients with sepsis are still very limited. For sepsis, improving ventilation is one of the main treatments. Nitric oxide (NO) and almitrine have been reported to improve oxygenation in patients with "classical" sepsis. Here, we conducted a systematic review and meta-analysis to evaluate the efficacy and safety of NO, almitrine, and the combination of both for COVID-19 (at the edge of sepsis) patients. Method: A systematic search was performed on Embase, PubMed, the Cochrane Library, the Web of Science, Wanfang Data, and China National Knowledge Infrastructure. Randomized clinical trials, cohort studies, cross-sectional studies, case-control studies, case series, and case reports in COVID-19 patients with suspected or confirmed sepsis were performed. Study characteristics, patient demographics, interventions, and outcomes were extracted from eligible articles. Results: A total of 35 studies representing 1,701 patients met eligibility criteria. Inhaled NO did not affect the mortality (OR 0.96, 95% CI 0.33–2.8, I 2 = 81%, very low certainty), hospital length of stay (SMD 0.62, 95% CI 0.04–1.17, I 2 = 83%, very low certainty), and intubation needs (OR 0.82, 95% CI 0.34–1.93, I 2 = 56%, very low certainty) of patients with COVID-19 (at the edge of sepsis). Meanwhile, almitrine did not affect the mortality (OR 0.44, 95% CI 0.17–1.13, low certainty), hospital length of stay (SMD 0.00, 95% CI -0.29–0.29, low certainty), intubation needs (OR 0.94, 95% CI 0.5–1.79, low certainty), and SAEs (OR 1.16, 95% CI 0.63–2.15, low certainty). Compared with pre-administration, the PaO 2 /FiO 2 of patients with NO (SMD-0.87, 95% CI -1.08–0.66, I 2 = 0%, very low certainty), almitrine (SMD-0.73, 95% CI-1.06–0.4, I 2 = 1%, very low certainty), and the combination of both (SMD-0.94, 95% CI-1.71–0.16, I 2 = 47%, very low certainty) increased significantly. Conclusion: Inhaled NO, almitrine, and the combination of the two drugs improved oxygenation significantly, but did not affect the patients' mortality, hospitalization duration, and intubation needs. Almitrine did not significantly increase the patients' SAEs. Well-designed high-quality studies are needed for establishing a stronger quality of evidence. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=367667, identifier CRD42022367667.

Inhaled nitric oxide: can it serve as a savior for COVID-19 and related respiratory and cardiovascular diseases?

Saying no to SARS-CoV-2: the potential of nitric oxide in the treatment of COVID-19 pneumonia

More questions than answers for the use of inhaled nitric oxide in COVID-19

The Role of NO in COVID-19 and Potential Therapeutic Strategies

The Potential Role of Nitric Oxide as a Therapeutic Agent against SARS-CoV-2 Infection

Inhaled nitric oxide: role in the pathophysiology of cardio-cerebrovascular and respiratory diseases

Inhaled Nitric Oxide in Preterm and Term Neonates with Hypoxemic Respiratory Failure and Persistent Pulmonary Hypertension

Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19

Nitric oxide as a double-edged sword in pulmonary viral infections: Mechanistic insights and potential therapeutic implications

Nitric oxide mediated hypoxia dynamics in COVID-19

Delivery of Nitric Oxide in the Cardiovascular System: Implications for Clinical Diagnosis and Therapy

Impact of Inhaled Nitric Oxide (iNO) on the Outcome of COVID-19 Associated ARDS

Inhaled nitric oxide in moderate-to-severe COVID-19 acute respiratory distress syndrome: a retrospective cohort study

Clinical experience of high-flow nasal cannula oxygen therapy in severe COVID-19 patients

Impact of low dose inhaled nitric oxide treatment in spontaneously breathing and intubated COVID-19 patients: a retrospective propensity-matched study

[Clinical experience of high-flow nasal cannula oxygen therapy in severe corona virus disease 2019 (COVID-19) patients].

Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections

The acute effect of inhaled nitric oxide on the exercise capacity of patients with advanced interstitial lung disease: a randomized controlled trial

Unraveling the impact of nitric oxide, almitrine, and their combination in COVID-19 (at the edge of sepsis) patients: a systematic review

Clinical Progress of Nitric Oxide for Treating Acute Respiratory Distress Sysdrome

A novel pre-clinical strategy to deliver antimicrobial doses of inhaled nitric oxide